483 related articles for article (PubMed ID: 30367208)
1. Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity.
Ohtani K; Fujino T; Ide T; Funakoshi K; Sakamoto I; Hiasa KI; Higo T; Kamezaki K; Akashi K; Tsutsui H
Clin Res Cardiol; 2019 Jun; 108(6):600-611. PubMed ID: 30367208
[TBL] [Abstract][Full Text] [Related]
2. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.
Armenian SH; Hudson MM; Chen MH; Colan SD; Lindenfeld L; Mills G; Siyahian A; Gelehrter S; Dang H; Hein W; Green DM; Robison LL; Wong FL; Douglas PS; Bhatia S
BMC Cardiovasc Disord; 2016 Oct; 16(1):187. PubMed ID: 27716152
[TBL] [Abstract][Full Text] [Related]
5. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
[TBL] [Abstract][Full Text] [Related]
6. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
[TBL] [Abstract][Full Text] [Related]
7. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
8. Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity.
Khan AA; Ashraf A; Singh R; Rahim A; Rostom W; Hussain M; Renner I; Collins NJ
Intern Med J; 2017 Jan; 47(1):104-109. PubMed ID: 27800661
[TBL] [Abstract][Full Text] [Related]
9. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
Cardinale D; Colombo A; Bacchiani G; Tedeschi I; Meroni CA; Veglia F; Civelli M; Lamantia G; Colombo N; Curigliano G; Fiorentini C; Cipolla CM
Circulation; 2015 Jun; 131(22):1981-8. PubMed ID: 25948538
[TBL] [Abstract][Full Text] [Related]
10. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines.
Mousavi N; Tan TC; Ali M; Halpern EF; Wang L; Scherrer-Crosbie M
Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):977-84. PubMed ID: 25925220
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.
Ferreira de Souza T; Quinaglia A C Silva T; Osorio Costa F; Shah R; Neilan TG; Velloso L; Nadruz W; Brenelli F; Sposito AC; Matos-Souza JR; Cendes F; Coelho OR; Jerosch-Herold M; Coelho-Filho OR
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1045-1055. PubMed ID: 30092965
[TBL] [Abstract][Full Text] [Related]
12. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
Janbabai G; Nabati M; Faghihinia M; Azizi S; Borhani S; Yazdani J
Cardiovasc Toxicol; 2017 Apr; 17(2):130-139. PubMed ID: 27003392
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
[TBL] [Abstract][Full Text] [Related]
14. The early variation of left ventricular twisting function in patients with lymphoma received anthracycline therapy assessed by three-dimensional speckle tracking echocardiography.
Song F; Kang Y; Zhang C; Xu Y; Shi J; Guo Y; Zhang Q; Shu X; Cheng L
Cardiol J; 2017; 24(5):484-494. PubMed ID: 28353310
[TBL] [Abstract][Full Text] [Related]
15. Importance of baseline heart rate as a predictor of cardiac functional recovery in newly diagnosed heart failure with reduced ejection fraction.
Valika A; Paprockas K; Villines D; Costanzo MR
Clin Cardiol; 2018 Jun; 41(6):752-757. PubMed ID: 29512170
[TBL] [Abstract][Full Text] [Related]
16. Left atrial reservoir longitudinal strain and its incremental value to the left ventricular global longitudinal strain in predicting anthracycline-induced cardiotoxicity.
Li Z; Zhao R; Zhang Q; Shen Y; Shu X; Cheng L
Echocardiography; 2024 Apr; 41(4):e15805. PubMed ID: 38558436
[TBL] [Abstract][Full Text] [Related]
17. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
18. Left ventricular strain and strain rates are decreased in children with normal fractional shortening after exposure to anthracycline chemotherapy.
Moon TJ; Miyamoto SD; Younoszai AK; Landeck BF
Cardiol Young; 2014 Oct; 24(5):854-65. PubMed ID: 24044518
[TBL] [Abstract][Full Text] [Related]
19. Early Detection of Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivors With T2 Cardiac Magnetic Resonance.
Lustberg MB; Reinbolt R; Addison D; Ruppert AS; Moore S; Carothers S; Suresh A; Das H; Berger M; Ramaswamy B; Wesolowski R; Binkley P; Raman SV; Shapiro CL
Circ Cardiovasc Imaging; 2019 May; 12(5):e008777. PubMed ID: 31060375
[No Abstract] [Full Text] [Related]
20. Identification of a novel microRNA profile in pediatric patients with cancer treated with anthracycline chemotherapy.
Oatmen KE; Toro-Salazar OH; Hauser K; Zellars KN; Mason KC; Hor K; Gillan E; Zeiss CJ; Gatti DM; Spinale FG
Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1443-H1452. PubMed ID: 30141982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
